COLOR trial results presented as Late Breaking Trial at EuroPCR 2021!

Tom Meijers, MD, presented the main results of the COLOR trial during the LBT Session on 18^th May 2021 at the online EuroPCR congress.

The COLOR trial showed that transradial PCI is associated with less clinically significant access-site related complications as compared to transfemoral PCI for complex coronary lesions using large-bore guiding catheters.

“With the insights of this trial, the radial artery should be the primary choice of access for complex PCI as well when large-bore guidings are mandated, improving patient safety with similar procedural efficacy,” said Maarten van Leeuwen, MD PhD (principal investigator of the COLOR trial).

The COLOR trial is an international, multicenter, prospective, randomized clinical trial enrolling 388 patients in twelve centers in Europe (The Netherlands, Belgium, Germany, United Kingdom and Switzerland). Patients were randomized to either 7 Fr slender radial access or 7 Fr femoral access. The primary endpoint was defined as BARC 2, 3 or 5 bleeding or vascular complication requiring intervention related to the randomised access site at discharge.

COLOR showed for the first time in subjects indicated for complex PCI:

• 7 Fr transradial access leads to significantly less relevant access site related complications compared to 7 Fr transfemoral access
• Procedural efficacy was highly comparable between both randomized strategies

The main paper has been published in JACC Cardiovascular Interventions simultaneously with the EuroPCR congress.

Watch the full presentation here.